DrugPatentWatch Database Preview
Drugs in Development Information for Vadadustat
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Vadadustat?
Vadadustat is an investigational drug.
There have been 24 clinical trials for Vadadustat.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are Akebia Therapeutics, Mitsubishi Tanabe Pharma Corporation, and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
There are thirteen US patents protecting this investigational drug and one hundred and twenty-four international patents.
Summary for Vadadustat
| US Patents | 13 |
| International Patents | 124 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2015-12-01) |
| Vendors | 29 |
Recent Clinical Trials for Vadadustat
| Title | Sponsor | Phase |
|---|---|---|
| Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat | Akebia Therapeutics | Phase 1 |
| Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) | Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) | Phase 3 |
| Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) | Akebia Therapeutics | Phase 3 |
Clinical Trial Summary for Vadadustat
Top disease conditions for Vadadustat
Top clinical trial sponsors for Vadadustat
US Patents for Vadadustat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vadadustat | Start Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| Vadadustat | Start Trial | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | Akebia Therapeutics, Inc. (Cambridge, MA) | Start Trial |
| Vadadustat | Start Trial | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (Pajardo, PR) | Start Trial |
| Vadadustat | Start Trial | Prolyl hydroxylase inhibitors and methods of use | Akebia Therapeutics Inc. (Cincinnati, OH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vadadustat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vadadustat | Argentina | 099354 | 2033-11-15 | Start Trial |
| Vadadustat | Australia | 2014348523 | 2033-11-15 | Start Trial |
| Vadadustat | Australia | 2019202144 | 2033-11-15 | Start Trial |
| Vadadustat | Brazil | 112016011065 | 2033-11-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
